Company intelligence / Profile preview

Gemina Laboratories

Burnaby, British Columbia, Canadageminalabs.com ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

Gemina Laboratories has commercialized rapid point-of-care lateral flow tests for COVID‑19 and influenza A/B. Their LEGIO X COVID‑19 rapid antigen test is approved; the LEGIO XI multiplex device detects both influenza types A and B with no cross-reactivity. Additional pipeline products include tests for respiratory syncytial virus and tuberculosis. The company’s technology is available for licensing to other diagnostics companies.

Therapeutic areas: Infectious Diseases
Modalities: DeviceBiosensor
Industry: Protein Biomarker Diagnostics

Drug pipeline

2 assets

LEGIO X

Commercial

Indications: Respiratory diseases

1 more asset in the full pipeline.

Request access →

Partnerships

RAPIvD

Beyond the preview

Go deeper on Gemina Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gemina Laboratories.

Explore the full profile